Back to today’s briefing

Story perspectives

UCLA Develops Inhalable Gene Therapy for Cystic Fibrosis

3/4/2025

50 10

Summary

Story summary

UCLA researchers are pioneering an inhalable gene-editing platform designed to combat cystic fibrosis by targeting lung stem cells with lipid nanoparticles. This groundbreaking method seeks to rectify the CFTR gene mutation, igniting hope for patients who have not responded to existing therapies. Additionally, this technology holds promise for treating other genetic disorders, including muscular dystrophy and sickle cell disease.

1 of 1

Story summary

UCLA researchers are pioneering an inhalable gene-editing platform designed to combat cystic fibrosis by targeting lung stem cells with lipid nanoparticles. This groundbreaking method seeks to rectify the CFTR gene mutation, igniting hope for patients who have not responded to existing therapies. Additionally, this technology holds promise for treating other genetic disorders, including muscular dystrophy and sickle cell disease.